miR-99 Family of microRNAs Suppresses the Expression of Prostate Specific Antigen and Prostate Cancer Cell Proliferation MicroRNAs (miRNAs) have been globally profiled in cancers but there tends to be poor agreement between studies including in the same cancers. Additionally, few putative miRNA targets have been validated. To overcome the lack of reproducibility, scientists profiled miRNAs by next generation sequencing and locked nucleic acid miRNA microarrays, and verified concordant changes by quantitative RT-PCR. [Cancer Res]
Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at info@connexoncreative.com
First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer Accuray Incorporated announced the first published five-year outcomes on low risk prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System. [Press release from Accuray Incorporated discussing online prepublication in Radiation Oncology]
Scientists Now Know Why Some Cancers Become Malignant and Others Don’t Cancer cells reproduce by dividing in two, but a molecule known as PML limits how many times this can happen, according to researchers. [Press release from the University of Montreal discussing online prepublication in Genes and Development]
Regulation of E2Fs and Senescence by PML Nuclear Bodies Scientists show that the mechanism by which promyelocytic leukemia protein (PML) induces a permanent cell cycle exit and activates p53 and senescence involves a recruitment of E2F transcription factors bound to their promoters and the retinoblastoma proteins to PML nuclear bodies enriched in heterochromatin proteins and protein phosphatase 1-alpha. [Genes Dev]
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014 BIND Biosciences announced that it has initiated a Phase I clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. [BIND Biosciences Press Release]
$1 Million Dollar Prostate Cancer Foundation Opportunity These two-year awards will provide a total of $1 million per team. This round of awards will focus on funding Treatment Science: studies of new ideas in man or laboratory support of a high impact clinical investigation. [Dana-Farber/Harvard Cancer Center Press Release]
Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost. Visit here to post your career opportunities.